Table 1.
Baseline characteristics of HCC patients in the effective and ineffective groups
| Characteristic | Effective group (n=67) |
Ineffective group (n=51) |
P-value |
|---|---|---|---|
| Age (years) | 58.96±10.25 | 56.12±9.80 | 0.131 |
| Gender (male) | 37 (55.2) | 27 (52.9) | 0.805 |
| Pathological type | 0.020 | ||
| Primary liver cancer | 38 (56.7) | 21 (41.2) | |
| Gastric cancer metastasis | 16 (23.9) | 8 (16.7) | |
| Adenosquamous carcinoma | 13 (19.4) | 22 (43.1) | |
| TNM stage | 0.025 | ||
| I | 21 (31.3) | 12 (23.5) | |
| II | 18 (26.9) | 26 (51.0) | |
| III | 28 (41.8) | 13 (25.5) | |
| Tumor regression rate | 53 (79.1) | 31 (60.8) | 0.030 |
| History of liver disease | 31 (46.3) | 14 (27.5) | 0.037 |
| Positive HBsAg | 32 (47.8) | 34 (66.7) | 0.040 |
| AFP (ng/mL) | 0.508 | ||
| 20–400 | 18 (26.9) | 11 (21.6) | |
| >400 | 49 (73.1) | 40 (78.4) | |
| Incidence of cirrhosis | 46 (68.7) | 24 (47.1) | 0.018 |
| Nodular type | 0.974 | ||
| Multiple nodule | 17 (25.4) | 12 (23.5) | |
| Macro nodule | 23 (34.3) | 18 (35.3) | |
| Single tumor nodule | 27 (40.3) | 21 (41.2) |
Note: Data presented as n (%) or mean ± standard deviation.
Abbreviations: HCC, hepatocellular carcinoma; TNM, tumor–node–metastasis; HBsAg, hepatitis B surface antigen; AFP, alpha fetoprotein.